Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Long-distance skiing confers benefit for hypertension

3 days ago

Participating in a long-distance skiing event may help lower the risk of hypertension, with the number of completed races showing a weak association with the risk, a study has found.

The study used data from Vasaloppet, an annual long-distance cross-country ski race, and included 206,889 skiers, as well as 505,542 matched nonskiers randomly sampled from the general population. There were 83,202 events of incident hypertension (skiers: 15,053; nonskiers: 70,149) recorded over a time-at-risk of 6,388,174 years. Median age at inclusion was 38.7 years.

In Cox analysis, the incidence of hypertension during a median time-at-risk of 8.3 years was lower in skiers vs nonskiers (hazard ratio [HR], 0.59, 95 percent confidence interval [CI], 0.58–0.60). The better the performance (in percentage of winning time) in Vasaloppet, the lower the incidence of hypertension (fastest fifth: HR, 0.41, 95 percent CI, 0.39–0.42; slowest fifth: HR, 0.78, 95 percent CI, 0.75–0.81). This association was near linear and similar in men and women.

There was a weak association observed between the number of completed races during the study period and incident hypertension among the skiers (one race: HR, 0.63, 95 percent CI, 0.62–0.65; more than five races: HR, 0.51, 95 percent CI, 0.50–0.53).

Results were consistent in a subgroup analysis of 10,804 participants that evaluated the impact of lifestyle factors.

The present data highlight the potential beneficial effects of high or very high physical fitness on the risk of hypertension, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.